The stream · Daily digest
The stream: Tuesday, November 10, 2026
13 briefs from ClinicalTrials.gov, FDA and the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 9
-
NEB and Mammoth Biosciences launch MB-CasFire enzyme for one-pot isothermal assays
NEB will manufacture and globally distribute Mammoth Biosciences' proprietary MB-CasFire enzyme, a thermostable Type V CRISPR nuclease that works across 37-65 °C and can be coupled directly with LAMP, RPA and NEAR assays. MB-CasFire resolves targets at single-nucleotide resolution and simplifies assay architecture by eliminating the need for multiple temperature incubations or component additions.
Source: Company press release (PR Newswire), November 10, 2026
-
ISTx registers Phase 3 trial of ceftobiprole in pediatric Staphylococcus aureus bacteremia
The study, led by ISTx, LLC, plans to enroll 60 participants and begin on October 30, 2026, to compare ceftobiprole with standard-of-care antibiotics in children under 18 with Staphylococcus aureus bacteremia, including right-sided infective endocarditis. The trial will also evaluate safety, tolerability, efficacy, and pharmacokinetics of ceftobiprole.
Source: ClinicalTrials.gov registry record, November 10, 2026
-
Sanofi registers Phase 3 trial of venglustat vs Cerezyme in pediatric Gaucher disease type 3
The study, titled LEAP2KIDS, plans to enroll 18 pediatric participants aged 2 to 11 years with Gaucher Disease Type III who have reached therapeutic goals with enzyme replacement therapy. It is a randomized, open-label, active-comparator trial with a 52-week primary analysis period and a 52-week extended treatment period.
Source: ClinicalTrials.gov registry record, November 10, 2026
-
Boehringer Ingelheim registers Phase 3 safety rollover trial of obrixtamig in advanced cancer
The study, first posted on ClinicalTrials.gov on November 10, 2026, plans to enroll 68 participants and begin in March 2027. It plans to find out how well participants who received obrixtamig in a previous study tolerate the drug.
Source: ClinicalTrials.gov registry record, November 10, 2026
-
Apellis posts results of Pegcetacoplan long-term safety extension study
The study, completed on September 4, 2025, enrolled 137 participants who had previously completed a pegcetacoplan study. It was an open-label, non-randomized, multi-center Phase 3 extension study evaluating long-term safety and efficacy in PNH.
Source: ClinicalTrials.gov results record, November 10, 2026
-
Alcon posts results of Phase 3 FID 123320 study
The study enrolled 284 participants and was completed with results first posted on ClinicalTrials.gov on November 10, 2026. It assessed the safety and efficacy of FID 123320 Ophthalmic Solution (Apraclonidine HCl 0.125%) versus vehicle for relieving ocular redness in pediatric and adult populations.
Source: ClinicalTrials.gov results record, November 10, 2026
-
Genmab posts results of Phase 3 epcoritamab trial in relapsed/refractory DLBCL in China
Results for the study were first posted on ClinicalTrials.gov on November 10, 2026. The trial enrolled 72 participants who were randomized to receive epcoritamab or investigator's choice chemotherapy for relapsed/refractory diffuse large B-cell lymphoma.
Source: ClinicalTrials.gov results record, November 10, 2026
-
Alcon posts results of Phase 3 apraclonidine study for ocular redness
The study enrolled 159 participants and was completed on November 14, 2024. Results were first posted on ClinicalTrials.gov on November 10, 2026.
Source: ClinicalTrials.gov results record, November 10, 2026
-
Survodutide shows no increased cardiovascular risk in obesity trial
The authors reported that in the SYNCHRONIZE-CVOT phase 3 trial, 136 of 3671 participants receiving survodutide experienced the primary composite endpoint versus 76 of 1836 receiving placebo (HR 0·89 [95% CI 0·67-1·18]). Gastrointestinal adverse events were more frequent with survodutide, with nausea in 48·0%-49·0% and vomiting in 31·7%-34·0% of participants.
Source: PubMed record of a Phase III journal article, November 9, 2026
Policy · 2
-
Eli Lilly launches Life Doesn't Slow Down campaign for Foundayo
The company announced a new campaign encouraging patients to discuss weight-loss options with doctors. The campaign highlights Foundayo, a GLP-1 pill approved by the FDA in April 2026, and features comedian Leanne Morgan as a spokesperson.
Source: Company press release (PR Newswire), November 10, 2026
-
IMVIONIX acquires U.S. and Canadian rights to BEOVU
IMVIONIX Inc. announced it has acquired exclusive commercial rights to BEOVU (brolucizumab-dbll) in the United States and Canada from Novartis, marking the company's official commercial launch. BEOVU is FDA-approved for treating neovascular (wet) age-related macular degeneration and diabetic macular edema.
Source: Company press release (PR Newswire), November 10, 2026
Approvals · 1
-
FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
On November 10, 2026, the FDA approved pimicotinib (Pimjetmi, EMD Serono, Inc.) for adults with symptomatic TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity. The approval follows a double-blind, randomized, placebo-controlled MANEUVER trial that evaluated pimicotinib 50 mg once daily.
Source: FDA approval notification, November 10, 2026
Regulation · 1
-
FDA partially grants petition to remove methylene chloride as color additive diluent
The order removes a solvent used as a diluent in inks for marking fruit and vegetables, effective January 11, 2027. Requests to remove ethylene dichloride and trichloroethylene from extraction solvents for annatto, paprika, and turmeric were denied because residues would be impurities not covered by the Delaney Clause.
Source: Federal Register rule, November 10, 2026